Zoledronate Prevents Morphometric Vertebral Fractures Over 10 Years
By Elana Gotkine HealthDay Reporter
WEDNESDAY, Jan. 15, 2025 -- For early postmenopausal women, zoledronate administered at baseline and five years is effective for preventing morphometric vertebral fracture, according to a study published in the Jan. 16 issue of the New England Journal of Medicine.
Mark J. Bolland, M.B., Ch.B., Ph.D., from the University of Auckland in New Zealand, and colleagues conducted a 10-year prospective double-blind trial involving early postmenopausal women (age 50 to 60 years) with bone mineral density T scores lower than 0 and higher than −2.5 at the lumbar spine, femoral neck, or hip. Participants were randomly assigned to receive an infusion of zoledronate (5 mg) at baseline and at five years (zoledronate-zoledronate group), zoledronate (5 mg) at baseline and placebo at five years (zoledronate-placebo group), or placebo at both baseline and five years (placebo-placebo group).
Overall, 1,003 of the 1,054 women completed 10 years of follow-up. The researchers found that 6.3, 6.6, and 11.1 percent of women in the zoledronate-zoledronate, zoledronate-placebo, and placebo-placebo groups, respectively, had a new morphometric fracture (relative risks, 0.56 and 0.59 for zoledronate-zoledronate and zoledronate-placebo, respectively, versus placebo-placebo). The relative risks of fragility fracture, any fracture, and major osteoporotic fracture were 0.72, 0.70, and 0.60, respectively, and 0.79, 0.77, and 0.71, respectively, for zoledronate-zoledronate versus placebo-placebo and for zoledronate-placebo versus placebo-placebo.
"Intravenous zoledronate administered once every five years reduced the incidence of morphometric vertebral fractures during a 10-year period," the authors write.
Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted January 2025
Read this next
Regular Sexual Activity Linked to Fewer Genitourinary-Related Symptoms in Menopause
THURSDAY, July 3, 2025 -- Regular sexual activity is associated with a lower prevalence of genitourinary syndrome of menopause (GSM)-related symptoms, according to a study...
Weighted Vests Do Not Prevent Weight Loss-Linked Bone Loss at Hip
TUESDAY, July 1, 2025 -- For older adults with obesity, neither weighted vest use nor resistance training (RT) mitigates weight loss (WL)-associated bone loss at the hip...
Moderate-to-Severe Asthma Up for Female Permanent Night Shift Workers
THURSDAY, June 26, 2025 -- Female permanent night shift workers have higher odds of moderate-to-severe asthma than female day workers, but this relationship is not seen in men...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.